Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a Phase III clinical trial for its proprietary bispecific antibody drug conjugate (ADC), BL-B01D1. This innovative therapy is being evaluated for the treatment of recurrent small-cell lung cancer (SCLC) in patients who have previously not responded to platinum-based chemotherapy and anti-PD-1/PD-L1 monoclonal antibody therapies.
In addition, a separate Phase III trial for BL-B01D1 targeting locally advanced, recurrent, or metastatic HR+/HER2- breast cancer also initiated its first patient dosing in May of this year. Notably, the molecule was at the center of an impressive USD 8.4 billion licensing agreement with U.S. pharmaceutical giant Bristol-Myers Squibb, finalized at the end of 2023.- Flcube.com
